{
  "$type": "site.standard.document",
  "path": "/2026/02/05/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan/",
  "publishedAt": "2026-02-05T11:44:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan. […]",
  "title": "Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan"
}